{"ResultsReport": {"xmlns": "http://integration.foundationmedicine.com/reporting", "xmlnsxsi": "http://www.w3.org/2001/XMLSchema_instance", "xsischemaLocation": "http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd", "CustomerInformation": {"ReferenceID": "01_2022_00019451", "CSN": null, "TRF": "ORD_1321264_01", "MRN": "41190196", "PhysicianId": "109266", "NPI": "International"}, "ResultsPayload": {"FinalReport": {"xmlnsxsd": "http://www.w3.org/2001/XMLSchema", "StagingId": "1058575", "clinicalId": "1059946", "xsinoNamespaceSchemaLocation": "http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd", "Application": {"ApplicationSettings": {"ApplicationSetting": {"Name": "Statement", "Value": null}}}, "DemographicCorrectionDate": null, "ReportId": "ORD_1321264_01", "SampleName": "US1270856.01", "Version": "0", "Sample": {"FM_Id": "ORD_1321264_01", "SampleId": "US1270856.01", "BlockId": "S111-07110A", "TRFNumber": "ORD_1321264_01", "TestType": "FoundationOne CDx             ", "SpecFormat": "FFPE", "ReceivedDate": "2022_03_14", "processSites": {"processSite": [{"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "LC"}, {"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "Extracted DNA"}]}, "TumorPurity": "40", "SpecimenLocation": "nan"}, "PMI": {"ReportId": "S111-98806", "MRN": "41190196", "FullName": "\u6d2a\u7fca\u5ead", "FirstName": "41190196", "LastName": "41190196", "SubmittedDiagnosis": " Anaplastic oligodendroglioma, Cerebrum", "Gender": "Female", "DOB": "1974_01_14", "OrderingMD": "\u8a31\u79c9\u6b0a", "OrderingMDId": "109266", "Pathologist": "\u5468\u5fb7\u76c8", "CopiedPhysician1": null, "MedFacilName": "Taipei Veterans General Hospital", "MedFacilID": "205872", "SpecSite": "Brain", "CollDate": "2022_02_22", "ReceivedDate": "2022-03-25 00:00:00", "CountryOfOrigin": "TW", "TumorType": "Diffuse Glioma"}, "PertinentNegatives": null, "Summaries": {"alterationCount": "14", "clinicalTrialCount": "10", "resistiveCount": "0", "sensitizingCount": "1"}, "VariantProperties": {"VariantProperty": [{"geneName": "ERBB2", "isVUS": "true", "variantName": "P378L"}, {"geneName": "IGF1R", "isVUS": "true", "variantName": "T345A"}, {"geneName": "KMT2A (MLL)", "isVUS": "true", "variantName": "A53V"}, {"geneName": "MLL2", "isVUS": "true", "variantName": "R1709H,R3508Q"}, {"geneName": "MSH6", "isVUS": "true", "variantName": "K1358fs*2"}, {"geneName": "RAD51B", "isVUS": "true", "variantName": "H378Y"}]}, "priorTests": null, "Genes": {"Gene": [{"Name": "IDH1", "Include": "true", "Alterations": {"Alteration": {"Name": "R132H", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "R132H"}}, "Interpretation": "The isocitrate dehydrogenases IDH1 and IDH2 encode highly homologous enzymes that are involved in the citric acid (TCA) cycle and other metabolic processes, playing roles in normal cellular metabolism and in protection against oxidative stress and apoptosis (Reitman and Yan, 2010; 20513808). R132 is located within the active site of IDH1 and is a hotspot for mutations in cancer (Jin et al., 2011; 21326614, Gross et al., 2010; 20142433, Ward et al., 2010; 20171147, Leonardi et al., 2012; 22442146, Reitman and Yan, 2010; 20513808). Substitutions at IDH1 R132 alter the enzymatic activity of IDH1, resulting in the production of the oncometabolite, D_2_hydroxyglutarate (2_HG)(Dang et al., 2009; 19935646, Ward et al., 2012; 21996744, Ward et al., 2010; 20171147, Gross et al., 2010; 20142433, Leonardi et al., 2012; 22442146), which promotes tumorigenesis (Gross et al., 2010; 20142433, Figueroa et al., 2010; 21130701, Xu et al., 2011; 21251613, Turcan et al., 2012; 22343889, Duncan et al., 2012; 22899282). IDH1 mutation is characteristic of low_grade gliomas and secondary glioblastoma, and is relatively rare in primary glioblastoma (Chaumeil et al., 2013; 24019001, Hartmann et al., 2013; 23918605, Rossetto et al., 2011; 21885076, Shin et al., 2013; 24129546, Parsons et al., 2008; 18772396). In the TCGA datasets, IDH1 mutation has been found in 77% of lower grade glioma cases and in 5% of glioblastoma cases (Cancer Genome Atlas Research Network., 2015; 26061751, cBio_Brennan et al., 2013; 24120142). IDH1 mutations are highly prevalent in grade 2 and grade 3 astrocytoma, oligodendroglioma, and oligoastrocytoma, reported in 43_100% of grade 2 tumors and 45_93% of grade 3 tumors (Thota et al., 2012; 22904127, Killela et al., 2013; 24140581, Haberler and W\u00f6hrer, 2014; 24559763, Yan et al., 2009; 19228619). Studies have reported that IDH mutation (IDH1 or IDH2) was associated with improved overall survival in glioma, including oligodendroglioma (Qi et al., 2011; 21874255, Shibahara et al., 2012; 21971842, Frenel et al., 2013; 23681562). This improvement in overall survival may be due to increased radiation sensitivity in gliomas with IDH mutation (Li et al., 2013; 23115158). In the context of IDH_mutated gliomas, TERT mutations are associated with improved OS (NCCN CNS Cancers Guidelines, v2.2021)(Arita et al., 2020; 33228806). IDH1/2 mutations are a strong favorable prognostic marker for OS in Grade 2_3 glioma, particularly in combination with 1p/19q codeletion (NCCN CNS Cancers Guidelines, v2.2021). Several studies have found IDH1 mutations to be associated with improved prognosis and longer PFS and OS in patients with various types of glioma including anaplastic astrocytoma and GBM (Hartmann et al., 2010; 21088844, Sonoda et al., 2009; 19765000, Ahmadi et al., 2012; 22528790, Jiang et al., 2013; 23486687, Shibahara et al., 2012; 21971842, Parsons et al., 2008; 18772396, Juratli et al., 2012; 23015095, Weller et al., 2009; 19805672). Co_occurrence of IDH1/2 mutation and chromosome 1p/19q co_deletion is associated with oligodendroglial features and the best patient prognosis, while co_occurrence of IDH1/2 mutation and ATRX mutation, without 1p/19q co_deletion, is associated with astrocytic features and intermediate prognosis, worse than that of patients with IDH1/2 mutation and 1p/19q co_deletion but significantly better than that of patients without IDH1/2 mutation (Haberler and W\u00f6hrer, 2014; 24559763). IDH1 mutations that lead to production of 2_HG, most commonly R132 alterations, may predict sensitivity to IDH1_mutation_specific inhibitors such as ivosidenib (Abou_Alfa et al., 2019; ESMO Abstract LBA10, Fan et al., 2019; 31028664, Mellinghoff et al., 2017; SNO Abstract ACTR_46, Tap et al., 2016; CTOS Abstract P1_138). A Phase 1b/2 study of the IDH1 inhibitor olutasidenib for patients with IDH1_mutated glioma reported a DCR of 50% (n=24) with 1 PR (De La Fuente et al., 2020; ASCO Abstract 2505). A Phase 1 study of the pan_IDH1/IDH2 inhibitor vorasidenib for patients with IDH1_ or IDH2_mutated glioma reported an ORR of 18.2% (4/22; RANO criteria) and median PFS of 31.4 months for non_enhancing cases and median PFS of 7.5 months for the overall glioma population (n=52) (Mellinghoff et al., 2020; ASCO Abstract 2504). Preclinical studies suggested that IDH1 neomorphic mutations may also confer sensitivity to PARP inhibitors (Philip et al., 2018; 29719265, Molenaar et al., 2018; 29339439, Lu et al., 2017; 28202508, Sulkowski et al., 2017; 28148839). In a Phase 1 trial of the PD_L1 inhibitor atezolizumab in patients with glioblastoma (GBM), 2 of the 3 patients with IDH1_mutant tumors experienced clinical benefit (1 PR and 1 long_term SD; the third patient experienced short_term SD), whereas none of the 8 patients with IDH1_wild_type GBM experienced benefit (8/8 PD); significantly longer PFS and a trend toward longer OS were observed in the patients with IDH1_mutated tumors compared to the patients with IDH1_wild_type tumors (Lukas et al., 2018; 30073642). Preclinical data indicate that IDH1_mutated glioma may be sensitive to the glutaminase inhibitor telaglenastat in combination with radiotherapy (McBrayer et al., 2018; 30220459, Kizilbash et al., 2019; ASCO Abstract TPS2075). IDH1/2 mutations are associated with improved survival outcomes for patients with glioma treated with radiation or alkylating chemotherapy (NCCN CNS Cancers Guidelines, v2.2021). Co_occurring TERT mutation, IDH mutation, and 1p/19q co_deletion is indicative of oligodendroglioma (NCCN CNS Cancers Guidelines, v2.2021)(Weller et al., 2020; 33293629). IDH1/2 mutation is associated with Grade 2 and 3 astrocytomas and oligodendrogliomas, and distinguishes secondary glioblastoma (GBM) from primary GBM (NCCN CNS Cancers Guidelines, v2.2021).", "Include": "true", "ClinicalTrialNote": "IDH1 mutations may predict sensitivity to IDH1 inhibitors. On the basis of preclinical data, IDH1 mutations may also confer sensitivity to PARP inhibitors in solid tumors. Preclinical data indicate that IDH1 mutations may predict sensitivity to glutaminase inhibitors.", "Therapies": {"Therapy": {"Name": null, "GenericName": "Ivosidenib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Ivosidenib is an isocitrate dehydrogenase 1 (IDH1) inhibitor that is FDA approved to treat patients with a susceptible IDH1 mutation in relapsed or refractory acute myeloid leukemia (AML) or previously treated locally advanced or metastatic cholangiocarcinoma. It is also approved as a first_line treatment for patients with AML and a susceptible IDH1 mutation who are not eligible for intensive induction chemotherapy or who are \u226575 years old. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of extensive clinical evidence in AML (DiNardo et al., 2018; 29860938) and cholangiocarcinoma (Lowery et al., 2019; 31300360, Abou_Alfa et al., 2020; 32416072) and limited clinical data in myelodysplastic syndrome (MDS) (DiNardo et al., 2018; 29860938) and glioma (Mellinghoff et al., 2020; 32530764, Fan et al., 2019; 31028664), IDH1 R132 mutation may confer sensitivity to ivosidenib. </p> <p><b>Supporting Data:</b> In a Phase 1 study of ivosidenib for patients with IDH1_mutated advanced solid tumors, 1 patient achieved PR in the non_enhancing glioma population (ORR=2.9% [1/35]); for patients with non_enhancing glioma and enhancing glioma, SD rates were 85.7% (30/35) and 45.2% (14/31), respectively, and median PFS was 13.6 months and 1.4 months, respectively (Mellinghoff et al., 2020; 32530764, Fan et al., 2019; 31028664). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}}, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT02264678", "Include": "true"}, {"nctId": "NCT04740190", "Include": "true"}, {"nctId": "NCT05035745", "Include": "true"}, {"nctId": "NCT03772561", "Include": "true"}, {"nctId": "NCT04801966", "Include": "true"}, {"nctId": "NCT03907969", "Include": "true"}, {"nctId": "NCT03830918", "Include": "true"}, {"nctId": "NCT03914742", "Include": "true"}, {"nctId": "NCT03212274", "Include": "true"}, {"nctId": "NCT03221400", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "CIC", "Include": "true", "Alterations": {"Alteration": {"Name": "S734fs*28", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "S734fs*28"}}, "Interpretation": "CIC encodes a transcriptional repressor that plays a role in central nervous system (CNS) development (Lee et al., 2002; 12393275). CIC inactivation has been reported in various malignancies, and is highly recurrent in oligodendroglioma (Bettegowda et al., 2011; 21817013, Yip et al., 2012; 22072542). CIC mutations have been described in various solid tumors, including 1\u201310% of sequenced gastric, endometrial, and colorectal carcinomas and melanoma tumors (cBioPortal, COSMIC, Jan 2022)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210, Tate et al., 2019; 30371878), although the consequences of CIC mutations in these tumor types have not been studied. CIC mutations have been observed in 58\u201369% of oligodendrogliomas but are less common in other gliomas, such as astrocytoma or oligoastrocytoma (Bettegowda et al., 2011; 21817013, Yip et al., 2012; 22072542, Sahm et al., 2012; 22588899). Published data investigating the prognostic implications of CIC alterations are generally limited (PubMed, Jun 2021). Conflicting data have been reported regarding the prognostic significance of CIC mutation in oligodendroglioma (Jiao et al., 2012; 22869205, Yip et al., 2012; 22072542, Chan et al., 2014; 24030748). There are no targeted therapies available to address genomic alterations in CIC.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "FUBP1", "Include": "true", "Alterations": {"Alteration": {"Name": "Q608*", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "Q608*"}}, "Interpretation": "FUBP1 encodes far upstream element binding protein 1 (also called FBP_1), a DNA_binding protein reported to have roles in transcriptional activation and splicing regulation of target genes. It is believed to act as an oncogene in some tumor types, such as hepatocellular carcinoma and non_small_cell lung cancer (Rabenhorst et al., 2009; 19637194, Singer et al., 2009; 19258502), and as a tumor suppressor in others, particularly oligodendroglioma, for which mutations and/or loss of FUBP1 often co_occur with alterations in CIC or IDH1 (Sahm et al., 2012; 22588899, Bettegowda et al., 2011; 21817013, Baumgarten et al., 2014; 24117486, Chan et al., 2014; 24030748, Jiao et al., 2012; 22869205). FUBP1 alteration has been reported in 1.5% of samples analyzed in COSMIC, with the highest incidences reported in tumors of the meninges (5%), endometrium (3%), central nervous system (3%), large intestine (3%), stomach (3%), liver (3%), and skin (2%) (COSMIC, 2022)(Tate et al., 2019; 30371878). One study reported higher expression of FUBP1 in colorectal carcinoma tissues compared to adenoma and normal colon epithelial tissues (Jia et al., 2014; 25030436). A genetic signature defined by concomitant alterations in IDH1, CIC, and FUBP1 is associated with longer survival in patients with glioma (Jiao et al., 2012; 22869205). FUBP1 has been shown to activate the expression of MYC (Duncan et al., 1994; 8125259, Kim et al., 2003; 12819782, Weber et al., 2008; 19087307, Jang et al., 2009; 19219071), activate p27KIP1 (Zheng et al., 2011; 21855647), and regulate the splicing of MDM2 (Jacob et al., 2014; 24798327). Therapies targeting FUBP1 mutation directly or downstream effectors have not been tested preclinically or clinically in tumors that harbor FUBP1 mutations.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "HDAC1", "Include": "true", "Alterations": {"Alteration": {"Name": "E398K", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "E398K"}}, "Interpretation": "HDAC1 encodes histone deacetylase 1, a protein that is involved in transcriptional repression (de Ruijter et al., 2003; 12429021). Aberrant activation or overexpression of HDAC1 has been associated with transcriptional repression of tumor suppressor regulatory activity, resulting in increased cellular proliferation (Halkidou et al., 2004; 15042618, Yoo et al., 2006; 16485345, Minucci et al., 2006; 16397526). In the TGCA datasets, HDAC1 amplification has been most frequently observed in ovarian serous cystadenocarcinoma (3%) (Cancer Genome Atlas Research Network., 2011; 21720365), esophagus_stomach cancer (1.9%) (Cancer Genome Atlas Research Network., 2017; 28052061), sarcoma (1.9%) (cBio_Barretina et al., 2010; 20601955), uterine corpus endometrial carcinomas (3%) (Cancer Genome Atlas Research Network., 2013; 23636398), and lung adenocarcinoma (1.7%) (Cancer Genome Atlas Research Network., 2014; 25079552). HDAC1 mutation has been observed less frequently in solid tumors, with the highest prevalence seen in tumors of the liver (2.2%), pancreas (2.2%), and skin (2.1%) and is rare in hematological malignancies (<1%) (COSMIC, 2021)(Tate et al., 2019; 30371878). Elevated HDAC1 protein expression has been correlated with a poor prognosis and diminished overall survival in patients with gastric, lung, pancreatic, and prostate cancer (Cao et al., 2017; 28767587, Weichert et al., 2008; 18207460, Wang et al., 2009; 19424621, Burdelski et al., 2015; 25794974). The HDAC inhibitors romidepsin, belinostat, and vorinostat have been approved in T_cell lymphomas, and panobinostat has been approved in multiple myeloma (Jones et al., 2016; 27629931). Other HDAC1 inhibitors are in development, and clinical trials are underway in a variety of solid and hematologic malignancies (Jones et al., 2016; 27629931). However, HDAC1 has not been clearly established as a sensitizing biomarker for these inhibitors (PubMed, 2021).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Microsatellite status", "Include": "true", "Alterations": {"Alteration": {"Name": "MS_Stable", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "MS_Stable"}}, "Interpretation": "Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). This sample is microsatellite_stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers (Boland et al., 1998; 9823339, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins (Kocarnik et al., 2015; 26337942, Bairwa et al., 2014; 24623249, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). Low_level MSI has been reported in 5_9% of glioblastoma (GBM) samples (Martinez et al., 2004; 15331927, Martinez et al., 2005; 15672285, Martinez et al., 2007; 17498554). A large_scale study did not find high_level microsatellite instability (MSI_H) in any of 129 GBM samples (Martinez et al., 2004; 15331927), although a small_scale study reported MSI_H in 4 of 15 pediatric GBMs and 1 of 12 adult GBMs (Szybka et al., 2003; 12908754). A pediatric patient with Lynch syndrome but MSS was reported to develop anaplastic oligodendroglioma (Heath et al., 2013; 23255519). The frequency of MSI has been reported to be increased in relapsed compared to primary GBM (Martinez et al., 2004; 15331927), in GBMs with a previous lower grade astrocytoma (Martinez et al., 2005; 15672285), and in giant cell GBM compared to classic GBM (Martinez et al., 2007; 17498554). A case study of a pediatric patient with glioblastoma with an oligodendroglioma component was reported to harbor MSI_high, which was proposed to be a possible mechanism of resistance to temozolomide treatment (Mizoguchi et al., 2013; 23530875). On the basis of clinical evidence, MSS tumors are significantly less likely than MSI_H tumors to respond to anti_PD_1 immune checkpoint inhibitors (Gatalica et al., 2014; 25392179, Kroemer et al., 2015; 26140250, Lal et al., 2015; 25949894), including approved therapies nivolumab and pembrolizumab (Overman et al., 2016; ASCO Abstract 3501, Le et al., 2015; 26028255). In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI_H and experienced a significantly higher ORR compared with non_MSI_H cases (70% vs. 12%, p=0.001) (Ayers et al., 2016; ASCO_SITC Abstract P60).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "TERT", "Include": "true", "Alterations": {"Alteration": {"Name": "promoter _146C>T", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "promoter _146C>T"}}, "Interpretation": "Telomerase reverse transcriptase (TERT, or hTERT) is a catalytic subunit of the telomerase complex, which is required to maintain appropriate chromosomal length (Shay et al., 2011; 22015685). Activation of TERT is a hallmark of cancer, being detected in up to 80_90% of malignancies and absent in quiescent cells (Shay et al., 1997; 9282118, Kim et al., 1994; 7605428, Hanahan and Weinberg, 2000; 10647931). Mutations within the promoter region of TERT that confer enhanced TERT promoter activity have been reported in two hotspots, located at _124 bp and _146 bp upstream of the transcriptional start site (also termed C228T and C250T, respectively)(Horn et al., 2013; 23348503, Huang et al., 2014; 23348506, Vinagre et al., 2013; 23887589), as well as tandem mutations at positions \u2013124/\u2013125 bp and \u2013138/\u2013139 bp (Horn et al., 2013; 23348503). TERT promoter mutations have been reported in 51_59% of gliomas (Killela et al., 2013; 23530248, Killela et al., 2014; 24722048), most frequently in glioblastoma (GBM, 54_84%), gliosarcoma (81%), oligodendroglioma (78%), and historically in oligoastrocytomas (25_31%) but less frequently in lower grade astrocytomas (10_18%) and in only 1% of ependymomas (Nonoguchi et al., 2013; 23955565, Liu et al., 2013; 23603989, Koelsche et al., 2013; 24154961, Killela et al., 2013; 23530248, Killela et al., 2014; 24722048). In the context of IDH_mutated gliomas, TERT mutations are associated with improved OS (NCCN CNS Cancers Guidelines, v2.2021)(Arita et al., 2020; 33228806). TERT promoter mutation has been shown to be significantly associated with increased TERT gene expression in astrocytoma, oligodendroglioma, and GBM (Arita et al., 2013; 23764841). TERT promoter mutations significantly associate with poor prognosis in patients with GBM, although this correlation may be due to the association with primary GBM as opposed to IDH_positive secondary GBM (Killela et al., 2013; 23530248, Nonoguchi et al., 2013; 23955565, Reitman et al., 2013; 24217890, Arita et al., 2013; 23764841). In the context of IDH_wildtype glioma, TERT mutations are associated with reduced OS (NCCN CNS Cancers Guidelines, v2.2021). Therapeutic options for targeting tumors with TERT mutations are limited, although a variety of approaches have been investigated, including immunotherapies using TERT as a tumor_associated antigen and antisense oligonucleotide_ or peptide_based therapies. TERT peptide vaccines showed limited anticancer efficacy in clinical trials (Zanetti et al., 2017; 27245281); however, in one preclinical study, the combination of a TERT peptide vaccine and anti_CTLA_4 therapy suppressed tumor growth (Duperret at al., 2018; 29249395). A Phase 2 study of the TERT inhibitor imetelstat for patients with advanced non_small cell lung cancer reported no improvement in PFS or OS (Chiappori et al., 2015; 25467017). Co_occurring TERT mutation, IDH mutation, and 1p/19q co_deletion is indicative of oligodendroglioma (NCCN CNS Cancers Guidelines, v2.2021)(Weller et al., 2020; 33293629). TERT mutations are associated with 1p/19q co_deletion in oligodendrogliomas, and are highly recurrent in IDH/ATRX_wildtype glioblastoma (GBM) (NCCN CNS Cancers Guidelines, v2.2021)(Weller et al., 2020; 33293629).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Tumor Mutation Burden", "Include": "true", "Alterations": {"Alteration": {"Name": "06", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "06"}}, "Interpretation": "Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). This sample harbors a TMB below levels that would be predicted to be associated with sensitivity to PD_1_ or PD_L1_targeting immune checkpoint inhibitors, alone or in combination with other agents (Touat et al., 2020; 32322066, Kamiya_Matsuoka et al., 2019; ESMO Abstract 393O, Zhao et al., 2019; 30742119, Samstein et al., 2019; 30643254, Bouffet et al., 2016; 27001570, Johanns et al., 2016; 27683556, Lukas et al., 2018; 30073642). The median TMB of oligodendrogliomas is 2.7 mutations per megabase (muts/Mb), and 8.4% of cases have high TMB (>20 muts/Mb)(FMI_Chalmers et al., 2017; 28420421). For pediatric patients, high TMB has been reported in a subset of high_grade gliomas, frequently in association with mutations in mismatch repair or proofreading genes and in TP53, whereas BRAF alterations or other oncogene fusions were observed more frequently in brain tumors harboring low TMB (Patel et al., 2020; 32386112, Johnson et al., 2017; 28912153). Increased TMB has been reported to correlate with higher tumor grade in glioma (Draaisma et al., 2015; 26699864) and glioblastoma (GBM) tissue samples with biallelic mismatch repair deficiency (bMMRD) (Bouffet et al., 2016; 27001570), as well as with shorter OS of patients with diffuse glioma (Wang et al., 2020; 32164609). On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Legrand et al., 2018; ASCO Abstract 12000, Samstein et al., 2019; 30643254, Goodman et al., 2017; 28835386, Goodman et al., 2019; 31405947), anti_PD_1 therapies (Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947), and combination nivolumab and ipilimumab (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Rizvi et al., 2017; WCLC Abstract 1106, Hellmann et al., 2018; 29731394, Rozeman et al., 2021; 33558721, Hodi et al., 2019; AACR abstract CT037, Lee et al., 2019; ASCO Abstract 641, Sharma et al., 2020; 32916128). In glioma, a lack of association between TMB and clinical benefit from immune checkpoint inhibitors has been reported (Kamiya_Matsuoka et al., 2019; ESMO Abstract 393O, Zhao et al., 2019; 30742119, Samstein et al., 2019; 30643254, Touat et al., 2020; 32322066). However, multiple case studies have reported that patients with ultramutated gliomas driven by POLE mutations have benefited from treatment with anti_PD_1 (Bouffet et al., 2016; 27001570, Johanns et al., 2016; 27683556) or anti_PD_L1 (Lukas et al., 2018; 30073642) therapies. Therefore, although increased TMB alone may not be a strong biomarker for PD_1 or PD_L1 inhibitors in this cancer type, these agents may have efficacy for patients with glioma harboring both high TMB and POLE mutation.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}]}, "Trials": {"Trial": [{"Gene": "IDH1", "Alteration": "R132H", "Title": "Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents", "StudyPhase": "PHASE 1/2", "Target": "ATR, PARP, PD_L1", "Locations": "Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Goyang_si (Korea, Republic of), Cambridge (United Kingdom), Withington (United Kingdom), Manchester (United Kingdom), Coventry (United Kingdom), Sutton (United Kingdom), Oxford (United Kingdom), Villejuif (France)", "NCTID": "NCT02264678", "Note": "IDH1 mutations may predict sensitivity to IDH1 inhibitors. On the basis of preclinical data, IDH1 mutations may also confer sensitivity to PARP inhibitors in solid tumors. Preclinical data indicate that IDH1 mutations may predict sensitivity to glutaminase inhibitors.", "Include": "true"}, {"Gene": "IDH1", "Alteration": "R132H", "Title": "Talazoparib _ Carboplatin for Recurrent High_grade Glioma With DDRd", "StudyPhase": "PHASE 2", "Target": "PARP", "Locations": "Hong Kong (Hong Kong)", "NCTID": "NCT04740190", "Note": "IDH1 mutations may predict sensitivity to IDH1 inhibitors. On the basis of preclinical data, IDH1 mutations may also confer sensitivity to PARP inhibitors in solid tumors. Preclinical data indicate that IDH1 mutations may predict sensitivity to glutaminase inhibitors.", "Include": "true"}, {"Gene": "IDH1", "Alteration": "R132H", "Title": "Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)", "StudyPhase": "PHASE 1/2", "Target": "XPO1, PARP", "Locations": "Singapore (Singapore)", "NCTID": "NCT05035745", "Note": "IDH1 mutations may predict sensitivity to IDH1 inhibitors. On the basis of preclinical data, IDH1 mutations may also confer sensitivity to PARP inhibitors in solid tumors. Preclinical data indicate that IDH1 mutations may predict sensitivity to glutaminase inhibitors.", "Include": "true"}, {"Gene": "IDH1", "Alteration": "R132H", "Title": "Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies", "StudyPhase": "PHASE 1", "Target": "PARP, AKTs, PD_L1", "Locations": "Singapore (Singapore)", "NCTID": "NCT03772561", "Note": "IDH1 mutations may predict sensitivity to IDH1 inhibitors. On the basis of preclinical data, IDH1 mutations may also confer sensitivity to PARP inhibitors in solid tumors. Preclinical data indicate that IDH1 mutations may predict sensitivity to glutaminase inhibitors.", "Include": "true"}, {"Gene": "IDH1", "Alteration": "R132H", "Title": "Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study", "StudyPhase": "PHASE null", "Target": "CDK4, CDK6, PI3K_alpha, PD_L1, MEK, PARP, PD_1, BRAF", "Locations": "Melbourne (Australia)", "NCTID": "NCT04801966", "Note": "IDH1 mutations may predict sensitivity to IDH1 inhibitors. On the basis of preclinical data, IDH1 mutations may also confer sensitivity to PARP inhibitors in solid tumors. Preclinical data indicate that IDH1 mutations may predict sensitivity to glutaminase inhibitors.", "Include": "true"}, {"Gene": "IDH1", "Alteration": "R132H", "Title": "A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti_cancer Agents in Patients With Advanced Cancers", "StudyPhase": "PHASE 1/2", "Target": "PARP, DNA_PK", "Locations": "Newcastle upon Tyne (United Kingdom), London (United Kingdom), Connecticut, Texas", "NCTID": "NCT03907969", "Note": "IDH1 mutations may predict sensitivity to IDH1 inhibitors. On the basis of preclinical data, IDH1 mutations may also confer sensitivity to PARP inhibitors in solid tumors. Preclinical data indicate that IDH1 mutations may predict sensitivity to glutaminase inhibitors.", "Include": "true"}, {"Gene": "IDH1", "Alteration": "R132H", "Title": "Niraparib and Temozolomide in Treating Patients With Extensive_Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum_Based First_Line Chemotherapy", "StudyPhase": "PHASE 1/2", "Target": "PARP", "Locations": "California", "NCTID": "NCT03830918", "Note": "IDH1 mutations may predict sensitivity to IDH1 inhibitors. On the basis of preclinical data, IDH1 mutations may also confer sensitivity to PARP inhibitors in solid tumors. Preclinical data indicate that IDH1 mutations may predict sensitivity to glutaminase inhibitors.", "Include": "true"}, {"Gene": "IDH1", "Alteration": "R132H", "Title": "BGB_290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations", "StudyPhase": "PHASE 1/2", "Target": "PARP", "Locations": "California, Michigan, Ohio, Massachusetts, Connecticut, Pennsylvania, Maryland, Virginia, North Carolina, Alabama", "NCTID": "NCT03914742", "Note": "IDH1 mutations may predict sensitivity to IDH1 inhibitors. On the basis of preclinical data, IDH1 mutations may also confer sensitivity to PARP inhibitors in solid tumors. Preclinical data indicate that IDH1 mutations may predict sensitivity to glutaminase inhibitors.", "Include": "true"}, {"Gene": "IDH1", "Alteration": "R132H", "Title": "Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations", "StudyPhase": "PHASE 2", "Target": "PARP", "Locations": "California, Wisconsin, Missouri, Kansas", "NCTID": "NCT03212274", "Note": "IDH1 mutations may predict sensitivity to IDH1 inhibitors. On the basis of preclinical data, IDH1 mutations may also confer sensitivity to PARP inhibitors in solid tumors. Preclinical data indicate that IDH1 mutations may predict sensitivity to glutaminase inhibitors.", "Include": "true"}, {"Gene": "IDH1", "Alteration": "R132H", "Title": "PEN_866 in Patients With Advanced Solid Malignancies", "StudyPhase": "PHASE 1/2", "Target": "PARP, HSP90", "Locations": "Nevada, Colorado, Nebraska, Wisconsin, Michigan, Oklahoma, Arkansas, Tennessee, Pennsylvania", "NCTID": "NCT03221400", "Note": "IDH1 mutations may predict sensitivity to IDH1 inhibitors. On the basis of preclinical data, IDH1 mutations may also confer sensitivity to PARP inhibitors in solid tumors. Preclinical data indicate that IDH1 mutations may predict sensitivity to glutaminase inhibitors.", "Include": "true"}]}, "References": {"Reference": [{"number": "0", "ReferenceId": "20513808", "FullCitation": "Reitman ZJ, et al. J. Natl. Cancer Inst. (2010) pmid: 20513808", "Include": "true"}, {"number": "1", "ReferenceId": "21326614", "FullCitation": "Jin G, et al. PLoS ONE (2011) pmid: 21326614", "Include": "true"}, {"number": "2", "ReferenceId": "20142433", "FullCitation": "Gross S, et al. J. Exp. Med. (2010) pmid: 20142433", "Include": "true"}, {"number": "3", "ReferenceId": "20171147", "FullCitation": "Ward PS, et al. Cancer Cell (2010) pmid: 20171147", "Include": "true"}, {"number": "4", "ReferenceId": "22442146", "FullCitation": "Leonardi R, et al. J. Biol. Chem. (2012) pmid: 22442146", "Include": "true"}, {"number": "5", "ReferenceId": "19935646", "FullCitation": "Dang L, et al. Nature (2009) pmid: 19935646", "Include": "true"}, {"number": "6", "ReferenceId": "21996744", "FullCitation": "Ward PS, et al. Oncogene (2012) pmid: 21996744", "Include": "true"}, {"number": "7", "ReferenceId": "21130701", "FullCitation": "Figueroa ME, et al. Cancer Cell (2010) pmid: 21130701", "Include": "true"}, {"number": "8", "ReferenceId": "21251613", "FullCitation": "Xu W, et al. Cancer Cell (2011) pmid: 21251613", "Include": "true"}, {"number": "9", "ReferenceId": "22343889", "FullCitation": "Turcan S, et al. Nature (2012) pmid: 22343889", "Include": "true"}, {"number": "10", "ReferenceId": "22899282", "FullCitation": "Duncan CG, et al. Genome Res. (2012) pmid: 22899282", "Include": "true"}, {"number": "11", "ReferenceId": "24019001", "FullCitation": "Chaumeil MM, et al. Nat Commun (2013) pmid: 24019001", "Include": "true"}, {"number": "12", "ReferenceId": "23918605", "FullCitation": "Hartmann C, et al. Clin. Cancer Res. (2013) pmid: 23918605", "Include": "true"}, {"number": "13", "ReferenceId": "21885076", "FullCitation": "Rossetto M, et al. Rev. Neurol. (Paris) (2011) pmid: 21885076", "Include": "true"}, {"number": "14", "ReferenceId": "24129546", "FullCitation": "Shin JH, et al. J. Neurooncol. (2013) pmid: 24129546", "Include": "true"}, {"number": "15", "ReferenceId": "18772396", "FullCitation": "Parsons DW, et al. Science (2008) pmid: 18772396", "Include": "true"}, {"number": "16", "ReferenceId": "26061751", "FullCitation": "Cancer Genome Atlas Research Network, et al. N. Engl. J. Med. (2015) pmid: 26061751", "Include": "true"}, {"number": "17", "ReferenceId": "24120142", "FullCitation": "Brennan CW, et al. Cell (2013) pmid: 24120142", "Include": "true"}, {"number": "18", "ReferenceId": "22904127", "FullCitation": "Thota B, et al. Am. J. Clin. Pathol. (2012) pmid: 22904127", "Include": "true"}, {"number": "19", "ReferenceId": "24140581", "FullCitation": "Killela PJ, et al. Oncotarget (2014) pmid: 24140581", "Include": "true"}, {"number": "20", "ReferenceId": "24559763", "FullCitation": "Haberler C, et al. Clin. Neuropathol. () pmid: 24559763", "Include": "true"}, {"number": "21", "ReferenceId": "19228619", "FullCitation": "Yan H, et al. N. Engl. J. Med. (2009) pmid: 19228619", "Include": "true"}, {"number": "22", "ReferenceId": "21874255", "FullCitation": "Qi ST, et al. Oncol. Rep. (2011) pmid: 21874255", "Include": "true"}, {"number": "23", "ReferenceId": "21971842", "FullCitation": "Shibahara I, et al. Int. J. Clin. Oncol. (2012) pmid: 21971842", "Include": "true"}, {"number": "24", "ReferenceId": "23681562", "FullCitation": "Frenel JS, et al. J. Neurooncol. (2013) pmid: 23681562", "Include": "true"}, {"number": "25", "ReferenceId": "23115158", "FullCitation": "Li S, et al. Neuro_oncology (2013) pmid: 23115158", "Include": "true"}, {"number": "26", "ReferenceId": "33228806", "FullCitation": "Arita H, et al. Acta Neuropathol Commun (2020) pmid: 33228806", "Include": "true"}, {"number": "27", "ReferenceId": "21088844", "FullCitation": "Hartmann C, et al. Acta Neuropathol. (2010) pmid: 21088844", "Include": "true"}, {"number": "28", "ReferenceId": "19765000", "FullCitation": "Sonoda Y, et al. Cancer Sci. (2009) pmid: 19765000", "Include": "true"}, {"number": "29", "ReferenceId": "22528790", "FullCitation": "Ahmadi R, et al. J. Neurooncol. (2012) pmid: 22528790", "Include": "true"}, {"number": "30", "ReferenceId": "23486687", "FullCitation": "Jiang H, et al. Neuro_oncology (2013) pmid: 23486687", "Include": "true"}, {"number": "31", "ReferenceId": "23015095", "FullCitation": "Juratli TA, et al. J. Neurooncol. (2012) pmid: 23015095", "Include": "true"}, {"number": "32", "ReferenceId": "19805672", "FullCitation": "Weller M, et al. J. Clin. Oncol. (2009) pmid: 19805672", "Include": "true"}, {"number": "33", "ReferenceId": "31028664", "FullCitation": "Fan B, et al. Invest New Drugs (2019) pmid: 31028664", "Include": "true"}, {"number": "34", "ReferenceId": "29719265", "FullCitation": "Philip B, et al. Cell Rep (2018) pmid: 29719265", "Include": "true"}, {"number": "35", "ReferenceId": "29339439", "FullCitation": "Molenaar RJ, et al. Clin. Cancer Res. (2018) pmid: 29339439", "Include": "true"}, {"number": "36", "ReferenceId": "28202508", "FullCitation": "Lu Y, et al. Cancer Res. (2017) pmid: 28202508", "Include": "true"}, {"number": "37", "ReferenceId": "28148839", "FullCitation": "Sulkowski PL, et al. Sci Transl Med (2017) pmid: 28148839", "Include": "true"}, {"number": "38", "ReferenceId": "30073642", "FullCitation": "Lukas RV, et al. J. Neurooncol. (2018) pmid: 30073642", "Include": "true"}, {"number": "39", "ReferenceId": "30220459", "FullCitation": "McBrayer SK, et al. Cell (2018) pmid: 30220459", "Include": "true"}, {"number": "40", "ReferenceId": "33293629", "FullCitation": "Weller M, et al. Nat Rev Clin Oncol (2021) pmid: 33293629", "Include": "true"}, {"number": "41", "ReferenceId": "12429021", "FullCitation": "de Ruijter AJ, et al. Biochem. J. (2003) pmid: 12429021", "Include": "true"}, {"number": "42", "ReferenceId": "15042618", "FullCitation": "Halkidou K, et al. Prostate (2004) pmid: 15042618", "Include": "true"}, {"number": "43", "ReferenceId": "16485345", "FullCitation": "Yoo CB, et al. Nat Rev Drug Discov (2006) pmid: 16485345", "Include": "true"}, {"number": "44", "ReferenceId": "16397526", "FullCitation": "Minucci S, et al. Nat. Rev. Cancer (2006) pmid: 16397526", "Include": "true"}, {"number": "45", "ReferenceId": "21720365", "FullCitation": "Nature (2011) pmid: 21720365", "Include": "true"}, {"number": "46", "ReferenceId": "28052061", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2017) pmid: 28052061", "Include": "true"}, {"number": "47", "ReferenceId": "20601955", "FullCitation": "Barretina J, et al. Nat. Genet. (2010) pmid: 20601955", "Include": "true"}, {"number": "48", "ReferenceId": "23636398", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398", "Include": "true"}, {"number": "49", "ReferenceId": "25079552", "FullCitation": "Nature (2014) pmid: 25079552", "Include": "true"}, {"number": "50", "ReferenceId": "30371878", "FullCitation": "Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878", "Include": "true"}, {"number": "51", "ReferenceId": "28767587", "FullCitation": "Cao LL, et al. Medicine (Baltimore) (2017) pmid: 28767587", "Include": "true"}, {"number": "52", "ReferenceId": "18207460", "FullCitation": "Weichert W, et al. Lancet Oncol. (2008) pmid: 18207460", "Include": "true"}, {"number": "53", "ReferenceId": "19424621", "FullCitation": "Wang W, et al. Oncol. Rep. (2009) pmid: 19424621", "Include": "true"}, {"number": "54", "ReferenceId": "25794974", "FullCitation": "Burdelski C, et al. Exp. Mol. Pathol. (2015) pmid: 25794974", "Include": "true"}, {"number": "55", "ReferenceId": "27629931", "FullCitation": "Jones PA, et al. Nat. Rev. Genet. (2016) pmid: 27629931", "Include": "true"}, {"number": "56", "ReferenceId": "12393275", "FullCitation": "Lee CJ, et al. Brain Res. Mol. Brain Res. (2002) pmid: 12393275", "Include": "true"}, {"number": "57", "ReferenceId": "21817013", "FullCitation": "Bettegowda C, et al. Science (2011) pmid: 21817013", "Include": "true"}, {"number": "58", "ReferenceId": "22072542", "FullCitation": "Yip S, et al. J. Pathol. (2012) pmid: 22072542", "Include": "true"}, {"number": "59", "ReferenceId": "22588877", "FullCitation": "Cerami E, et al. Cancer Discov (2012) pmid: 22588877", "Include": "true"}, {"number": "60", "ReferenceId": "23550210", "FullCitation": "Gao J, et al. Sci Signal (2013) pmid: 23550210", "Include": "true"}, {"number": "61", "ReferenceId": "22588899", "FullCitation": "Sahm F, et al. Acta Neuropathol. (2012) pmid: 22588899", "Include": "true"}, {"number": "62", "ReferenceId": "22869205", "FullCitation": "Jiao Y, et al. Oncotarget (2012) pmid: 22869205", "Include": "true"}, {"number": "63", "ReferenceId": "24030748", "FullCitation": "Chan AK, et al. Mod. Pathol. (2014) pmid: 24030748", "Include": "true"}, {"number": "64", "ReferenceId": "15748635", "FullCitation": "Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635", "Include": "true"}, {"number": "65", "ReferenceId": "23875803", "FullCitation": "Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803", "Include": "true"}, {"number": "66", "ReferenceId": "12379884", "FullCitation": "Pfeifer GP, et al. Oncogene (2002) pmid: 12379884", "Include": "true"}, {"number": "67", "ReferenceId": "25765070", "FullCitation": "Rizvi NA, et al. Science (2015) pmid: 25765070", "Include": "true"}, {"number": "68", "ReferenceId": "24336570", "FullCitation": "Johnson BE, et al. Science (2014) pmid: 24336570", "Include": "true"}, {"number": "69", "ReferenceId": "29452419", "FullCitation": "Choi S, et al. Neuro_oncology (2018) pmid: 29452419", "Include": "true"}, {"number": "70", "ReferenceId": "23447401", "FullCitation": "Briggs S, et al. J. Pathol. (2013) pmid: 23447401", "Include": "true"}, {"number": "71", "ReferenceId": "24583393", "FullCitation": "Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393", "Include": "true"}, {"number": "72", "ReferenceId": "22810696", "FullCitation": "Nature (2012) pmid: 22810696", "Include": "true"}, {"number": "73", "ReferenceId": "25568919", "FullCitation": "Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919", "Include": "true"}, {"number": "74", "ReferenceId": "32322066", "FullCitation": "Touat M, et al. Nature (2020) pmid: 32322066", "Include": "true"}, {"number": "75", "ReferenceId": "30742119", "FullCitation": "Zhao J, et al. Nat. Med. (2019) pmid: 30742119", "Include": "true"}, {"number": "76", "ReferenceId": "30643254", "FullCitation": "Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254", "Include": "true"}, {"number": "77", "ReferenceId": "27001570", "FullCitation": "Bouffet E, et al. J. Clin. Oncol. (2016) pmid: 27001570", "Include": "true"}, {"number": "78", "ReferenceId": "27683556", "FullCitation": "Johanns TM, et al. Cancer Discov (2016) pmid: 27683556", "Include": "true"}, {"number": "79", "ReferenceId": "28420421", "FullCitation": "Chalmers ZR, et al. Genome Med (2017) pmid: 28420421", "Include": "true"}, {"number": "80", "ReferenceId": "32386112", "FullCitation": "Patel RR, et al. Pediatr Blood Cancer (2020) pmid: 32386112", "Include": "true"}, {"number": "81", "ReferenceId": "28912153", "FullCitation": "Johnson A, et al. Oncologist (2017) pmid: 28912153", "Include": "true"}, {"number": "82", "ReferenceId": "26699864", "FullCitation": "Draaisma K, et al. Acta Neuropathol Commun (2015) pmid: 26699864", "Include": "true"}, {"number": "83", "ReferenceId": "32164609", "FullCitation": "Wang L, et al. BMC Cancer (2020) pmid: 32164609", "Include": "true"}, {"number": "84", "ReferenceId": "28835386", "FullCitation": "Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386", "Include": "true"}, {"number": "85", "ReferenceId": "31405947", "FullCitation": "Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947", "Include": "true"}, {"number": "86", "ReferenceId": "30309915", "FullCitation": "Cristescu R, et al. Science (2018) pmid: 30309915", "Include": "true"}, {"number": "87", "ReferenceId": "30785829", "FullCitation": "Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829", "Include": "true"}, {"number": "88", "ReferenceId": "29658845", "FullCitation": "Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845", "Include": "true"}, {"number": "89", "ReferenceId": "29657128", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128", "Include": "true"}, {"number": "90", "ReferenceId": "29731394", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394", "Include": "true"}, {"number": "91", "ReferenceId": "33558721", "FullCitation": "Rozeman EA, et al. Nat Med (2021) pmid: 33558721", "Include": "true"}, {"number": "92", "ReferenceId": "32916128", "FullCitation": "Sharma P, et al. Cancer Cell (2020) pmid: 32916128", "Include": "true"}, {"number": "93", "ReferenceId": "26337942", "FullCitation": "Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942", "Include": "true"}, {"number": "94", "ReferenceId": "21081928", "FullCitation": "You JF, et al. Br. J. Cancer (2010) pmid: 21081928", "Include": "true"}, {"number": "95", "ReferenceId": "24623249", "FullCitation": "Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249", "Include": "true"}, {"number": "96", "ReferenceId": "9823339", "FullCitation": "Boland CR, et al. Cancer Res. (1998) pmid: 9823339", "Include": "true"}, {"number": "97", "ReferenceId": "15528785", "FullCitation": "Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785", "Include": "true"}, {"number": "98", "ReferenceId": "20420947", "FullCitation": "Boland CR, et al. Gastroenterology (2010) pmid: 20420947", "Include": "true"}, {"number": "99", "ReferenceId": "15331927", "FullCitation": "Martinez R, et al. Oncology (2004) pmid: 15331927", "Include": "true"}, {"number": "100", "ReferenceId": "15672285", "FullCitation": "Martinez R, et al. J. Cancer Res. Clin. Oncol. (2005) pmid: 15672285", "Include": "true"}, {"number": "101", "ReferenceId": "17498554", "FullCitation": "Martinez R, et al. Cancer Genet. Cytogenet. (2007) pmid: 17498554", "Include": "true"}, {"number": "102", "ReferenceId": "12908754", "FullCitation": "Szybka M, et al. Clin. Neuropathol. () pmid: 12908754", "Include": "true"}, {"number": "103", "ReferenceId": "23255519", "FullCitation": "Heath JA, et al. Pediatr Blood Cancer (2013) pmid: 23255519", "Include": "true"}, {"number": "104", "ReferenceId": "23530875", "FullCitation": "Mizoguchi M, et al. Neuropathology (2013) pmid: 23530875", "Include": "true"}, {"number": "105", "ReferenceId": "25392179", "FullCitation": "Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179", "Include": "true"}, {"number": "106", "ReferenceId": "26140250", "FullCitation": "Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250", "Include": "true"}, {"number": "107", "ReferenceId": "25949894", "FullCitation": "Lal N, et al. Oncoimmunology (2015) pmid: 25949894", "Include": "true"}, {"number": "108", "ReferenceId": "26028255", "FullCitation": "Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255", "Include": "true"}, {"number": "109", "ReferenceId": "19637194", "FullCitation": "Rabenhorst U, et al. Hepatology (2009) pmid: 19637194", "Include": "true"}, {"number": "110", "ReferenceId": "19258502", "FullCitation": "Singer S, et al. Cancer Res. (2009) pmid: 19258502", "Include": "true"}, {"number": "111", "ReferenceId": "24117486", "FullCitation": "Baumgarten P, et al. Neuropathol. Appl. Neurobiol. (2014) pmid: 24117486", "Include": "true"}, {"number": "112", "ReferenceId": "25030436", "FullCitation": "Jia MY, et al. Neoplasma (2014) pmid: 25030436", "Include": "true"}, {"number": "113", "ReferenceId": "8125259", "FullCitation": "Duncan R, et al. Genes Dev. (1994) pmid: 8125259", "Include": "true"}, {"number": "114", "ReferenceId": "12819782", "FullCitation": "Kim MJ, et al. Nat. Genet. (2003) pmid: 12819782", "Include": "true"}, {"number": "115", "ReferenceId": "19087307", "FullCitation": "Weber A, et al. BMC Cancer (2008) pmid: 19087307", "Include": "true"}, {"number": "116", "ReferenceId": "19219071", "FullCitation": "Jang M, et al. Oncogene (2009) pmid: 19219071", "Include": "true"}, {"number": "117", "ReferenceId": "21855647", "FullCitation": "Zheng Y, et al. Int. J. Biochem. Cell Biol. (2011) pmid: 21855647", "Include": "true"}, {"number": "118", "ReferenceId": "24798327", "FullCitation": "Jacob AG, et al. J. Biol. Chem. (2014) pmid: 24798327", "Include": "true"}, {"number": "119", "ReferenceId": "22015685", "FullCitation": "Shay JW, et al. Semin. Cancer Biol. (2011) pmid: 22015685", "Include": "true"}, {"number": "120", "ReferenceId": "9282118", "FullCitation": "Shay JW, et al. Eur. J. Cancer (1997) pmid: 9282118", "Include": "true"}, {"number": "121", "ReferenceId": "7605428", "FullCitation": "Kim NW, et al. Science (1994) pmid: 7605428", "Include": "true"}, {"number": "122", "ReferenceId": "10647931", "FullCitation": "Hanahan D, et al. Cell (2000) pmid: 10647931", "Include": "true"}, {"number": "123", "ReferenceId": "23348503", "FullCitation": "Horn S, et al. Science (2013) pmid: 23348503", "Include": "true"}, {"number": "124", "ReferenceId": "23348506", "FullCitation": "Huang FW, et al. Science (2013) pmid: 23348506", "Include": "true"}, {"number": "125", "ReferenceId": "23887589", "FullCitation": "Vinagre J, et al. Nat Commun (2013) pmid: 23887589", "Include": "true"}, {"number": "126", "ReferenceId": "23530248", "FullCitation": "Killela PJ, et al. Proc. Natl. Acad. Sci. U.S.A. (2013) pmid: 23530248", "Include": "true"}, {"number": "127", "ReferenceId": "24722048", "FullCitation": "Killela PJ, et al. Oncotarget (2014) pmid: 24722048", "Include": "true"}, {"number": "128", "ReferenceId": "23955565", "FullCitation": "Nonoguchi N, et al. Acta Neuropathol. (2013) pmid: 23955565", "Include": "true"}, {"number": "129", "ReferenceId": "23603989", "FullCitation": "Liu X, et al. Cell Cycle (2013) pmid: 23603989", "Include": "true"}, {"number": "130", "ReferenceId": "24154961", "FullCitation": "Koelsche C, et al. Acta Neuropathol. (2013) pmid: 24154961", "Include": "true"}, {"number": "131", "ReferenceId": "23764841", "FullCitation": "Arita H, et al. Acta Neuropathol. (2013) pmid: 23764841", "Include": "true"}, {"number": "132", "ReferenceId": "24217890", "FullCitation": "Reitman ZJ, et al. Acta Neuropathol. (2013) pmid: 24217890", "Include": "true"}, {"number": "133", "ReferenceId": "27245281", "FullCitation": "Nat Rev Clin Oncol (2017) pmid: 27245281", "Include": "true"}, {"number": "134", "ReferenceId": "29249395", "FullCitation": "Duperret EK, et al. Mol Ther (2018) pmid: 29249395", "Include": "true"}, {"number": "135", "ReferenceId": "25467017", "FullCitation": "Chiappori AA, et al. Ann Oncol (2015) pmid: 25467017", "Include": "true"}, {"number": "136", "ReferenceId": "32530764", "FullCitation": "Mellinghoff IK, et al. J. Clin. Oncol. (2020) pmid: 32530764", "Include": "true"}, {"number": "137", "ReferenceId": "29860938", "FullCitation": "DiNardo CD, et al. N. Engl. J. Med. (2018) pmid: 29860938", "Include": "true"}, {"number": "138", "ReferenceId": "31300360", "FullCitation": "Lowery MA, et al. Lancet Gastroenterol Hepatol (2019) pmid: 31300360", "Include": "true"}, {"number": "139", "ReferenceId": "32416072", "FullCitation": "Abou_Alfa GK, et al. Lancet Oncol. (2020) pmid: 32416072", "Include": "true"}]}, "Signatures": {"Signature": {"ServerTime": "2022_03_21 21:11:04", "OpName": "Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director", "Text": "Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director"}}, "reportProperties": {"reportProperty": [{"identifier": "QualityControlMetrics", "key": "MedianCoverageValue", "value": "855x"}, {"identifier": "AdditionalFindings", "key": "TumorMutationBurdenScore", "value": "6 Muts/Mb"}, {"identifier": "AdditionalFindings", "key": "MicrosatelliteStatusScore", "value": "0 fraction_unstable_loci"}, {"identifier": "AdditionalFindings", "key": "LossOfHeterozygosityScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "BloodTumorMutationalBurdenScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "TumorFractionScore", "value": "Units Not Reported"}]}, "comments": null, "AAC": {"Amendmends": null}}, "variant_report": {"xmlns": "http://foundationmedicine.com/compbio/variant_report_external", "disease": "BRAIN", "disease_ontology": "Brain anaplastic oligodendroglioma", "flowcell_analysis": "2000020875", "gender": "female", "pathology_diagnosis": "Anaplastic oligodendroglioma", "percent_tumor_nuclei": "40", "pipeline_version": "v3.10.2", "purity_assessment": "89.2", "specimen": "ORD_1321264_01*US1270856.01", "study": "CLINICAL_F1CDx", "test_request": "ORD_1321264_01", "test_type": "FoundationOneDx", "tissue_of_origin": "Brain", "xsischemaLocation": "http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd", "samples": {"sample": {"bait_set": "DX1", "mean_exon_depth": "853.74", "name": "SQ_US1270856.01_1", "nucleic_acid_type": "DNA"}}, "quality_control": {"status": "Pass"}, "short_variants": {"short_variant": [{"allele_fraction": "0.474", "cds_effect": "_146C>T", "depth": "173", "equivocal": "false", "functional_effect": "promoter", "gene": "TERT", "percent_reads": "47.4", "position": "chr5:1295250", "protein_effect": "promoter _146C>T", "status": "known", "strand": "_", "transcript": "NM_198253", "dna_evidence": {"sample": "SQ_US1270856.01_1"}}, {"allele_fraction": "0.4426", "cds_effect": "1033A>G", "depth": "723", "equivocal": "false", "functional_effect": "missense", "gene": "IGF1R", "percent_reads": "44.26", "position": "chr15:99440065", "protein_effect": "T345A", "status": "unknown", "strand": "+", "transcript": "NM_000875", "dna_evidence": {"sample": "SQ_US1270856.01_1"}}, {"allele_fraction": "0.4818", "cds_effect": "5126G>A", "depth": "770", "equivocal": "false", "functional_effect": "missense", "gene": "MLL2", "percent_reads": "48.18", "position": "chr12:49438045", "protein_effect": "R1709H", "status": "unknown", "strand": "_", "transcript": "NM_003482", "dna_evidence": {"sample": "SQ_US1270856.01_1"}}, {"allele_fraction": "0.4982", "cds_effect": "10523G>A", "depth": "823", "equivocal": "false", "functional_effect": "missense", "gene": "MLL2", "percent_reads": "49.82", "position": "chr12:49428067", "protein_effect": "R3508Q", "status": "unknown", "strand": "_", "transcript": "NM_003482", "dna_evidence": {"sample": "SQ_US1270856.01_1"}}, {"allele_fraction": "0.5067", "cds_effect": "1132C>T", "depth": "596", "equivocal": "false", "functional_effect": "missense", "gene": "RAD51B", "percent_reads": "50.67", "position": "chr14:69061297", "protein_effect": "H378Y", "status": "unknown", "strand": "+", "transcript": "NM_133509", "dna_evidence": {"sample": "SQ_US1270856.01_1"}}, {"allele_fraction": "0.8144", "cds_effect": "2199_2201GTC>A", "depth": "404", "equivocal": "false", "functional_effect": "frameshift", "gene": "CIC", "percent_reads": "81.44", "position": "chr19:42795119", "protein_effect": "S734fs*28", "status": "likely", "strand": "+", "transcript": "NM_015125", "dna_evidence": {"sample": "SQ_US1270856.01_1"}}, {"allele_fraction": "0.5007", "cds_effect": "1133C>T", "depth": "711", "equivocal": "false", "functional_effect": "missense", "gene": "ERBB2", "percent_reads": "50.07", "position": "chr17:37868686", "protein_effect": "P378L", "status": "unknown", "strand": "+", "transcript": "NM_004448", "dna_evidence": {"sample": "SQ_US1270856.01_1"}}, {"allele_fraction": "0.8591", "cds_effect": "1822C>T", "depth": "440", "equivocal": "false", "functional_effect": "nonsense", "gene": "FUBP1", "percent_reads": "85.91", "position": "chr1:78414944", "protein_effect": "Q608*", "status": "likely", "strand": "_", "transcript": "NM_003902", "dna_evidence": {"sample": "SQ_US1270856.01_1"}}, {"allele_fraction": "0.4457", "cds_effect": "395G>A", "depth": "736", "equivocal": "false", "functional_effect": "missense", "gene": "IDH1", "percent_reads": "44.57", "position": "chr2:209113112", "protein_effect": "R132H", "status": "known", "strand": "_", "transcript": "NM_005896", "dna_evidence": {"sample": "SQ_US1270856.01_1"}}, {"allele_fraction": "0.9114", "cds_effect": "1192G>A", "depth": "395", "equivocal": "false", "functional_effect": "missense", "gene": "HDAC1", "percent_reads": "91.14", "position": "chr1:32797380", "protein_effect": "E398K", "status": "known", "strand": "+", "transcript": "NM_004964", "dna_evidence": {"sample": "SQ_US1270856.01_1"}}, {"allele_fraction": "0.4981", "cds_effect": "158C>T", "depth": "265", "equivocal": "false", "functional_effect": "missense", "gene": "MLL", "percent_reads": "49.81", "position": "chr11:118307385", "protein_effect": "A53V", "status": "unknown", "strand": "+", "transcript": "NM_005933", "dna_evidence": {"sample": "SQ_US1270856.01_1"}}, {"allele_fraction": "0.4835", "cds_effect": "4071_4072insGATT", "depth": "395", "equivocal": "false", "functional_effect": "frameshift", "gene": "MSH6", "percent_reads": "48.35", "position": "chr2:48033987", "protein_effect": "K1358fs*2", "status": "unknown", "strand": "+", "transcript": "NM_000179", "dna_evidence": {"sample": "SQ_US1270856.01_1"}}]}, "copy_number_alterations": null, "rearrangements": null, "biomarkers": {"microsatellite_instability": {"status": "MSS"}, "tumor_mutation_burden": {"score": "6.3", "status": "intermediate", "unit": "mutations_per_megabase"}}, "non_human_content": null}}}}